When the tumor volume grew to 50 mm3, PBS, 2 mg/kg of 5-FU, 2 mg/kg of the ERCC1–XPF blocker, and a combination of 2 mg/kg of 5-FU with 2 mg/kg of the ERCC1–XPF blocker was administered (Figure 4A). The gene discussed is ERCC1; the disease is neoplasm.